Association details:
Biomarker:KRAS A146
Cancer:Colorectal Cancer
Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
Evidence Level:
Sensitive: C3 – Early Trials

519 / 17 - Clinical impact ofKRASG12, G13, Q61, K117 and A146 mutations in patients with colorectal liver metastases

Published date:
For the subgroup of patients who carried a KRAS mutation and were treated with bevacizumab and doublet or triplet chemotherapy (N=156)....Moreover, KRAS A146 mutation carriers showed inferior overall survival compared to patients with mutations in KRAS G12 (median 10.7 versus 26.4 months; HR=2.5; p=0.003), and the multivariable Cox regression analysis showed that the KRAS alteration was the only independent prognostic factor for overall survival....This study revealed that within mCRC patients A146 is the third most common KRAS mutation variant, and mCRC patients carrying a KRAS A146 mutation represent a distinct molecular subtype of patients with high tumor burden and poor clinical outcome.
Secondary therapy: